ArticleFrontiers in oncology2023

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance.

Jusuf Imeri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.